In a letter to the Institute for Clinical and Economic Review (ICER), the Partnership to Improve Patient Care (PIPC) offered feedback on ICER's assessment of treatments for COVID-19. PIPC expressed disappointment in ICER's model for failing to capture both the full societal benefits of COVID-19 treatments, as well as the impact these treatments have on health equity. The letter also criticizes ICER's decision to rely on the discriminatory quality-adjusted-life-years (QALY) metric.
"The pandemic is also widely known to have exerted more harm on certain populations, including communities of color, people with disabilities, and individuals living with chronic illness," wrote PIPC Chair Tony Coelho. "PIPC urges ICER to revisit its modeling choices to ensure it is capturing the full benefit of effective COVID-19 treatments on society, including health equity considerations."